Lipella Pharmaceuticals (LIPO) Short Interest Ratio & Short Volume

Short interest is the volume of Lipella Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of March 15th, investors have sold 55,800 shares of LIPO short. 2.94% of Lipella Pharmaceuticals' shares are currently sold short. Learn More on Lipella Pharmaceuticals' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.94% of Lipella Pharmaceuticals' floating shares are currently sold short.

Lipella Pharmaceuticals saw a decline in short interest during the month of March. As of March 15th, there was short interest totaling 55,800 shares, a decline of 4.1% from the previous total of 58,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Lipella Pharmaceuticals currently has issued a total of 1,209,000 shares. Some of Lipella Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Lipella Pharmaceuticals currently has a public float of 1,900,000 shares.

2.94% of Lipella Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Lipella Pharmaceuticals: GeoVax Labs, Inc. (6.86%), Aprea Therapeutics, Inc. (1.17%), Trinity Biotech plc (1.33%), BioCardia, Inc. (1.38%), Sensei Biotherapeutics, Inc. (0.73%), Moleculin Biotech, Inc. (3.34%), BioLineRx Ltd. (5.61%), Talphera, Inc. (0.62%), PharmaCyte Biotech, Inc. (0.44%), Traws Pharma, Inc. (2.08%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($26.28 billion), iShares 20+ Year Treasury Bond ETF ($9.53 billion), MicroStrategy Incorporated ($8.50 billion), Apollo Global Management, Inc. ($4.86 billion), Super Micro Computer, Inc. ($4.85 billion), Charter Communications, Inc. ($4.28 billion), Capital One Financial Co. ($4.08 billion), AppLovin Co. ($3.82 billion), Canadian Natural Resources Limited ($3.78 billion), and Schlumberger Limited ($2.87 billion). View all of the most shorted stocks.

Short selling LIPO is an investing strategy that aims to generate trading profit from Lipella Pharmaceuticals as its price is falling. LIPO shares are trading down $0.13 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Lipella Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of LIPO, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including LIPO, twice per month. The most recent reporting period available is March, 15 2025.